Lightnews — Scholar-powered news

ACIR @acir-org.bsky.social · 15h

New targets uncovered to improve CAR-T. Read our double feature here 👉 bit.ly/4nN1lsS @broadinstitute.org @bocklab.bsky.social

ACIR @acir-org.bsky.social · 1d

To direct T cells toward carbohydrate antigens, Zhou et al. devised T cell engagers called GlyTRs by linking a glycan-binding lectin to an anti-CD3 scFv. bit.ly/42kcsRe

ACIR @acir-org.bsky.social · 2d

Liu et al. performed an in vivo CRISPR screen under selective pressure of anti-PD-1 therapy, and identified phosphatidylserine synthase 1 (PTDSS1) as a tumor-specific gene involved in regulating anti-PD-1 response. bit.ly/3KrJXLr @mdanderson.bsky.social @pamsharmamdphd.bsky.social

ACIR @acir-org.bsky.social · 5d

Analyzing samples from patients with TNBC before and after treatment with neoadjuvant anti-PD-1, Fu, Jin, He, Chen, and Yang et al. found that enrichment for IFN-induced senescent CD8+ T cells predicted non-response in patients with early-stage TNBC. bit.ly/3KOF92E

1

ACIR @acir-org.bsky.social · 5d

Andersson et al. described preclinical studies of ATOR-4066, a bispecific antibody that targets CEACAM5, which is expressed on most gastrointestinal carcinomas and others, and agonizes CD40. bit.ly/42jBGzb

1

ACIR @acir-org.bsky.social · 6d

Pauneto et al. demonstrated in patient samples and tumor models that hypoxic stress in the TME induced an integrated stress response (ISR) in tumor antigen-specific T cells through multiple ISR kinases. bit.ly/4mUxmOs

1

ACIR @acir-org.bsky.social · 6d

Fusi and Serger et al. showed that PD-1–IL2v, comprising a PD-1 blocking antibody and an IL-2Rα-non-binding IL-2 variant, induced antitumor T cell activity in human PBMCs and CD8+ and CD4+Foxp3- TILs in vitro. bit.ly/46wM5tP @unibas.ch

1

ACIR @acir-org.bsky.social · 7d

To overcome the resistance often seen with TROP2-targeted ADCs, Brea et al. engineered TROP2-targeted CAR T cells, including biparatopic CAR T cells targeting multiple TROP2 epitopes to limit antigen escape acir.org/weekly-dige... @danafarber.bsky.social

ACIR @acir-org.bsky.social · 9d

Uncovering a novel mechanism of immune resistance, Catherine Sautès-Fridman described how the derivatives of the neurometabolite gamma amino butyric acid (GABA) impact the immune system. Read more here 👉 acir.org/weekly-dige... #CICON25

ACIR @acir-org.bsky.social · 14d

We’ve rounded up 18 must-see talks from #CICON25. Catch the highlights in our digest. 👉 bit.ly/4pEy04Y.

1

ACIR @acir-org.bsky.social · 15d

CTNNB1S37F is a driver mutation found across solid tumors. Using an HLA+ cell line transduced with CTNNB1S37F, Eggebø et al. used MS to identify two HLA-bound neopeptides that were also expressed naturally on CTNNB1S37F+ tumor cells. bit.ly/4gtsj5T

1

ACIR @acir-org.bsky.social · 16d

Abrantes and Forcados et al. generated and characterized AM52.1, a pan-carcinoma antibody with exclusive specificity for a truncated O-glycan structure Sialyl-Tn antigen (STn), which is found on various epithelial tumors [...] bit.ly/42uU73N

1

ACIR @acir-org.bsky.social · 18d

Last week, our team had the privilege of attending CICON 2025 in Utrecht!
We’re putting together a digest of highlights from selected talks dropping on September 24.
Stay tuned for key takeaways you won’t want to miss.
#CICON25 #CancerImmunotherapy

ACIR @acir-org.bsky.social · 19d

Yang, Wang, and Fu et al. profiled 15 responding and 21 non-responding metastatic melanoma tumors and identified 14 cell types and 55 subtypes, including a mature dendritic cell subtype enriched in immunoregulatory [...] bit.ly/3Vm6mvL @manoliskellis.bsky.social

ACIR @acir-org.bsky.social · 19d

Lu and Luo et al. performed CRISPR screens in primary macrophages and identified lactic acid, PGE2, and GM-CSF as tumor-derived modulators of TAM polarization. bit.ly/3K4pbRT

2

ACIR @acir-org.bsky.social · 20d

Using scRNAseq data from patients with ICI-treated melanoma, Bae et al. profiled conventional CD4+ T cells (excluding Tregs and proliferative cells) at the lesion level. bit.ly/4nFmqVI

ACIR @acir-org.bsky.social · 20d

TCR KO supports allogeneic CAR T cells, but also results in CD3 antigen loss from the cell surface. bit.ly/3VTVyFj

ACIR @acir-org.bsky.social · 21d

New driver of T cell dysfunction in tumors uncovered 👉 bit.ly/4mgJAQV @delgoffelab.bsky.social

1

ACIR @acir-org.bsky.social · 29d

Using a sequential anchored transcription factor screen, Henriques-Oliveira, Altman, and Kurochkin et al. identified two transcription factor triads: PU.1, IRF4, and PRDM1 as inducers of cells similar to type 2 conventional DCs, and [...] bit.ly/4pbCGiO

ACIR @acir-org.bsky.social · Sep 8

Sidiropoulos et al. report state-of-the-art spatial genomics and proteomic profiling of PDAC tumors and tumor-adjacent lymph nodes from patients treated with GVAX and anti-PD-1 alone or in combination with [...] bit.ly/4m1SvFM @ltkagohara.bsky.social‬ @jhu.edu‬

ACIR @acir-org.bsky.social · Sep 5

Xing, Zhou, and Wang et al. demonstrated the role of CD103+CD8+ T cells in protection against breast cancer lung metastasis. bit.ly/46m1HA4

1

ACIR @acir-org.bsky.social · Sep 5

Hong et al. investigated sac-TMT, a TROP2-targeted antibody–drug conjugate, in combination with tagitanlimab (anti-PD-L1) as a first-line therapy in advanced NSCLC without actionable genomic alterations. bit.ly/4g3d6bo

ACIR @acir-org.bsky.social · Sep 4

Focusing on antigenic heterogeneity and antigen loss in solid tumors, Xiao, Wang, and He et al. engineered T cells to express FLT3L and XCL1 (FX). bit.ly/4pnTUJV

ACIR @acir-org.bsky.social · Sep 4

Singer and Pabón et al. developed a Salmonella typhimurium bacterial platform that delivered non-spreading, self-replicating viral RNA, even into cell types beyond the virus’s natural tropism. bit.ly/3I48J3i ‪@columbiauniversity.bsky.social‬

1 1 4

ACIR @acir-org.bsky.social · Sep 3

Azevedo et al. found that aberrant glycosylation drives T cell exhaustion, starting in early tumors ‪@delgoffelab.bsky.social‬. Read about it here: acir.org/weekly-dige...